VTAMA Drug Patent Profile

When do Vtama patents expire, and when can generic versions of Vtama launch?

Vtama is a drug marketed by Organon Llc and is included in one NDA. There are eleven patents protecting this drug.

This drug has eighty-one patent family members in thirty-nine countries.

The generic ingredient in VTAMA is tapinarof. One supplier is listed for this compound. Additional details are available on the tapinarof profile page.

DrugPatentWatch^® Generic Entry Outlook for Vtama

Vtama will be eligible for patent challenges on May 23, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 13, 2038. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for VTAMA

International Patents:	81
US Patents:	11
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	60
Patent Applications:	340
Drug Prices:	Drug price information for VTAMA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VTAMA
What excipients (inactive ingredients) are in VTAMA?	VTAMA excipients list
DailyMed Link:	VTAMA at DailyMed

See drug prices for VTAMA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VTAMA

NDA:

215272

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VTAMA

Drug Class	Aryl Hydrocarbon Receptor Agonist
Mechanism of Action	Aryl Hydrocarbon Receptor Agonists

US Patents and Regulatory Information for VTAMA

VTAMA is protected by thirteen US patents and two FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes			Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes				Y
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes
Organon Llc	VTAMA	tapinarof	CREAM;TOPICAL	215272-001	May 23, 2022		RX	Yes	Yes

International Patents for VTAMA

When does loss-of-exclusivity occur for VTAMA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

Chile

China

Colombia

European Patent Office

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VTAMA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2021502333	タピナロフを調製するためのプロセス
European Patent Office	3297605
Japan	6863904
Taiwan	201705940	Topical pharmaceutical compositions
Mexico	377629	COMPOSICIONES FARMACÉUTICAS TÓPICAS. (TOPICAL PHARMACEUTICAL COMPOSITIONS)

Market Dynamics and Financial Trajectory for VTAMA (Tapinarof)

Last updated: February 19, 2026

What is VTAMA, and what is its current market status?

VTAMA (tapinarof) is a topical aryl hydrocarbon receptor (AHR) modulating agent developed by Vicore Pharma and licensed to Dermavant Sciences. It received U.S. FDA approval in August 2022 for treating plaque psoriasis in adults. It is also under review or developing for other dermatological conditions, including atopic dermatitis.

Key Market Drivers

Unmet Medical Need in Dermatology

• Prevalence of plaque psoriasis: Approximately 2-3% globally, affecting over 125 million people.
• Treatment landscape: Dominated by corticosteroids, vitamin D analogs, and biologics; biologics have high efficacy but pose concerns over cost and administration complexity.
• Patient demand: The need for effective, non-biologic, topical therapies with a favorable safety profile supports VTAMA's market entry.

Competitive Positioning

• Unique mechanism: AHR modulation offers anti-inflammatory and skin barrier-restoring effects.
• Efficacy: Phase 3 trials demonstrated significant improvements in Psoriasis Area Severity Index (PASI) scores.
• Safety profile: Favorable adverse event profile positions VTAMA against biologic and systemic, which often have significant side effects.

Regulatory and Commercial Milestones

• FDA approval date: August 2022.
• US Launch: Initiated Q4 2022.
• Pricing strategy: Priced competitively relative to biologics, but at a premium to topical steroids.

Market Size and Revenue Projections

Initial Market Penetration

• Target population: Approximately 4-6 million adults in the U.S. with mild-to-moderate psoriasis.
• Pricing: Estimated at about $1,200 per tube (28 grams), based on similar topical treatments.
• Market capture: Targeting 10-15% of eligible patients in the first 3 years.

Revenue Projections (Next 5 Years)

Year	Estimated Patients Using VTAMA	Revenue ($ millions)	Assumptions
2023	250,000	300	5% penetration, initial launch phase
2024	600,000	720	Growth driven by expanded access
2025	1 million	1,200	Expanded formulary inclusion, increased awareness
2026	1.5 million	1,800	Greater insurance coverage, competitive positioning
2027	2 million	2,400	Saturation of accessible market

Global Expansion

• Europe: Potential launch in 2024; Europe’s psoriasis market is approximately $2 billion.
• Asia: Entry possible in 2025; target markets include Japan and Korea.

Competitive Landscape and Market Share

Competitors	Market Share (2023–2027)	Key Features
Topical corticosteroids	40-50%	Cost-effective, widely used, risk of side effects
Vitamin D analogs	20-30%	Used as adjuncts, some efficacy limitations
Topical calcineurin inhibitors	5-10%	Targeted, limited to specific populations
Biologics	25-30%	High efficacy, high cost, systemic nature
VTAMA	5-20% (target)	Non-steroidal, safe, convenient topical use

Regulatory and Reimbursement Considerations

• FDA approval: Based on Phase 3 data (VPO-001 study), demonstrating PASI-75 response rates of 35-38% at week 12.
• Reimbursement: Coverage depends on insurance policies favoring cost-effective topical options; initial access may be limited by formulary inclusion timelines.
• Label expansions: Trials into atopic dermatitis and other inflammatory skin conditions are ongoing, potentially broadening market potential.

Risks and Challenges

• Market penetration: Established use of corticosteroids and vitamin D analogs may slow initial uptake.
• Pricing pressures: Payers may push for discounts or prefer older, lower-cost therapies.
• Competitive innovations: New topical agents or biosimilars may enter the market, affecting market share.
• Regulatory delays: Pending approvals in Europe and Asia may impact global revenue timelines.

Key Takeaways

• VTAMA's FDA approval positions it as a novel topical therapy in dermatology, targeting a large unmet market.
• Revenue potential in the U.S. is projected between $300 million and $2.4 billion over five years, based on market penetration assumptions.
• Competitive advantage hinges on efficacy, safety, ease of use, and pricing relative to existing therapies.
• Expansion into international markets and indications could diversify revenue streams.

FAQs

1. What is the primary indication for VTAMA?
Treating plaque psoriasis in adults.

2. How does VTAMA differ from traditional psoriasis treatments?
It is a topical agent with a novel mechanism targeting the aryl hydrocarbon receptor, offering a non-steroidal, systemic-free therapy.

3. What are the key regulatory milestones for VTAMA?
FDA approval in August 2022; additional approvals are pending in Europe and other regions.

4. What is the expected timeline for global market expansion?
Europe in 2024, Asia by 2025, contingent on regulatory approvals and reimbursement landscape.

5. What are the primary risks to VTAMA's commercial success?
Market penetration challenges, pricing pressures, competition from established therapies, and regulatory delays.

---

Sources

[1] FDA (2022). U.S. Food and Drug Administration. "FDA approves Tapinarof for psoriasis."
[2] Vicore Pharma (2022). "VTAMA (Tapinarof) FDA approval announcement."
[3] Dermavant Sciences (2022). "Market analysis and launch strategies."
[4] GlobalData (2022). "Dermatology therapeutics market forecast."